# HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM

> **NCT00905060** · PHASE2 · COMPLETED · sponsor: **University of California, San Francisco** · enrollment: 70 (actual)

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **BIOLOGICAL:** HSPPC-96
- **DRUG:** Temozolomide
- **PROCEDURE:** Standard Surgical Resection

## Key facts

- **NCT ID:** NCT00905060
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06-29
- **Primary completion:** 2014-06-03
- **Final completion:** 2014-06-03
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2021-03-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00905060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00905060, "HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00905060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*